Ketorolac Tromethamine 10 MG/ML for Pain relief (KETO-APP Trial)

"Ketorolac Tromethamine 10 MG/ML is a Phase 3 medication, so it has received a score of 3 for safety. This means that there is both efficacy and multiple rounds of data supporting safety."

"According to the rules governing who can participate in this trial, the youngest patients that can be enrolled are 6 years old while the oldest eligible participants are 17."

"Yes, this is an ongoing study that was first posted on May 5th, 2021 and updated February 13th, 2022. They are looking for 100 participants at a single site."

"100 children aged 6 to 17 who present with abdominal pain at the emergency room will be admitted into this clinical trial. To meet the criteria for participation, patients must: have a physician or nurse's suspicion of appendicitis as reflected by the initiation of an appendicitis medical directive; have an IV cannula in place or ordered to be placed; have experienced moderate to severe pain for 5 days or less. Children ages 6 years old and younger are often atypical presentations of appendicitis and are thus excluded from the study."

"Yes, that is accurate. The clinical trial in question was posted on May 5th 2021 and last updated February 13th 2022. They are looking for 100 willing participants at a single location."

"This medication, Ketorolac Tromethamine 10 MG/ML, is most often given to patients in order to relieve ocular itching. However, it can also serve as an effective treatment for pain, pupil dilation, and induction of nerve block."

"As of right now, there are 97 ongoing studies into Ketorolac Tromethamine 10 MG/ML with 21 trials in the third and final phase. The majority of these clinical investigations are taking place in Boston, but Ketorolac Tromethamine 10 MG/ML is also being trialed at 189 other locations."